Absolute Antibody Receives £850K ($1.4M) Funding
Absolute Antibody Ltd, a life sciences company developing next generation engineered antibodies for biomedical research and diagnostics markets, has received £850K ($1.4 million) funding. The investment includes a £100K Smart proof-of-concept funding award from the Technology Strategy Board and £750K from the founders and a group of business angels.
The investment will be used to accelerate the growth of the business by building up its library of engineered antibodies and manufacturing capacity. The company has also announced the commercial launch of its suite of recombinant antibody services and catalogue of engineered antibody products, initially targeted at the research antibody market.
Absolute Antibody has developed a proprietary manufacturing platform based on transient transfection for the production of sequenced and engineered antibodies, AbsoluteAbs (AbAbs). These engineered antibodies provide a number of benefits over antibodies produced using traditional methods, including ultra-low batch-to-batch variability leading to improved reproducibility of results, and the ability to eliminate undesirable properties or add desirable features. For example, the binding potential for complement and Fc receptors can be eliminated to minimise background staining and provide cleaner results, while desirable features such as tags for detection and purification can be built into the AbAbs. The manufacture of AbAbs is fast, inexpensive and animal-free, with 100s of mgs generated within two weeks, versus up to three months required by traditional methods, enabling Absolute Antibody to offer vastly reduced time from order to delivery.
Dr Nick Hutchings, CEO of Absolute Antibody, said: "We would like to thank our investors for supporting the Company. The new funding allows us to accelerate the growth of our products and services. Absolute Antibody’s vision is to engineer antibodies that enable customers to achieve more reproducible and cleaner results, with new types of reagents and new formats. We believe Absolute Antibody will be at the forefront of the coming revolution in the £1.3 billion per year research antibody market.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance